Age: 63.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19-2
Symptoms: Hypertensive emergency, Metabolic function test, Microscopy, Rash, Troponin
Clinical narrative: elevated and uncontrolled BP/extremely high; Rash; hives; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 63-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 06Oct2022 as dose 5 (booster), single (Lot number: GJ3877) at the age of 63 years, in right arm for covid-19 immunisation. The patient's relevant medical history included: "Penicillin allergy" (unspecified if ongoing); "Sulfa allergy" (unspecified if ongoing). Concomitant medication(s) included: LEVOTHYROXINE; ATORVASTATIN. Past drug history included: Vancomycin, reaction(s): "Allergy"; Betadine, reaction(s): "Allergy"; Levaquin, reaction(s): "Allergy". Vaccination history included: BNT162b2 (Dose Number: 2, Batch/Lot No: ER8734, Location of injection: Arm Right), administration date: 05Apr2021, when the patient was 62-year-old, for COVID-19 immunization; BNT162b2 (Dose Number: 3, Batch/Lot No: 30155BA, Location of injection: Arm Right), administration date: 08Oct2021, when the patient was 62-year-old, for COVID-19 immunization; BNT162b2 (Dose Number: 4, Batch/Lot No: FJ4991), administration date: 12May2022, when the patient was 63-year-old, for COVID-19 immunization; Bnt162b2 (Dose Number: 1, Batch/Lot No: EL9266, Location of injection: Arm Left), administration date: Mar2022, for COVID-19 immunization. The following information was reported: RASH (non-serious) with onset Oct2022, outcome "not recovered"; URTICARIA (non-serious) with onset Oct2022, outcome "not recovered", described as "hives"; HYPERTENSION (medically significant) with onset Nov2022, outcome "not recovered", described as "elevated and uncontrolled BP/extremely high". The events "elevated and uncontrolled bp/extremely high", "rash" and "hives" required physician office visit and emergency room visit. The patient underwent the following laboratory tests and procedures: Blood pressure measurement: (2022) elevated and uncontrolled, notes: elevated and uncontrolled BP; (22Sep2022) Normal, notes: her BP was normal; (08Dec2022) Extremely high, notes: checked it on 08Dec2022 and it was extremely high; (Dec2022) High, notes: 2 weeks later it was still high. Therapeutic measures were taken as a result of hypertension, rash, urticaria.  Clinical course: Patient allegic to penicillin, levaquin, vancomycin, sulfa, betadine. Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Other medications the patient received within 2 weeks of vaccination included Valsartan, Levothyroxine, Atorvastatin. On 22Sep2022 her BP was normal, vaccine on 06Oct2022, rash and hives end of October. Not sure when the elevated and uncontrolled BP started but checked it on 08Dec2022 and it was extremely high. Dr doubled her dose of Valsartan. 2 weeks later it was still high. Doubled her dose again. Here we are another 2 weeks later and still elevated. Adverse event resulted in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Treatment received for the adverse event included doubled BP med dose. Patient not diagnosed with COVID-19 prior to vaccination. Patient had not been tested for covid 19 since the vaccination.